Clinical Trial Update: A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. [Phase 1, Phase 2]

View source ↗

Summary

A safety, tolerability, pharmacokinetics and efficacy study of GB261 in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is in Phase 1/2 with unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• GB261

Snippet

Sponsor: Genor Biopharma Co., Ltd. | Conditions: B Cell NHL, CLL | Phase 1, Phase 2 | Status: UNKNOWN